Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2026)
Kiniksa Pharmaceuticals International (KNSA) reported FCF Margin of 23.38% for Q1 2026, up 720.0% on a YoY basis from 2.85% in Q1 2025, and down 13.69% quarter-over-quarter from 27.08% in Q4 2025.
Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International has reported FCF Margin for 6 years, with the latest figure at 23.38% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin rose 720.0% year-over-year to 23.38%; the trailing twelve-month figure through Mar 2026 stood at 21.98% (up 1284.0% YoY), and the FY2025 full-year result was 20.35%, up 1432.0% from the prior year.
- FCF Margin for Q1 2026 stood at 23.38%, down from 27.08% in the prior quarter.
- The five-year high for FCF Margin was 62.57% in Q3 2022, with the low at 114.47% in Q1 2022.
- Historically, FCF Margin has averaged 4.04% across 5 years, with a median of 7.78% in 2022.
- Annual changes were most pronounced in 2022 — FCF Margin surged 47517 bps — and 2023, when it tumbled 3726 bps.
- Kiniksa Pharmaceuticals International's FCF Margin stood at 7.78% in 2022, then tumbled by 34 bps to 5.12% in 2023, then soared by 198 bps to 15.26% in 2024, then soared by 77 bps to 27.08% in 2025, then dropped by 14 bps to 23.38% in 2026.
- The last three FCF Margin figures came in at 23.38% (Q1 2026), 27.08% (Q4 2025), and 18.29% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | -5.22% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 12.86% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 46.39% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 16.78% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | -2.77% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -429.96% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 32.62% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 13.24% |
| 10 | Kiniksa Pharmaceuticals International | 3.76 Bn | 3.29 Bn | 193.47 Mn | 23.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.38% |
| Dec 31, 2025 | 27.08% |
| Sep 30, 2025 | 18.29% |
| Jun 30, 2025 | 17.72% |
| Mar 31, 2025 | 16.18% |
| Dec 31, 2024 | 15.26% |
| Sep 30, 2024 | -1.99% |
| Jun 30, 2024 | 4.77% |
| Mar 31, 2024 | 4.86% |
| Dec 31, 2023 | 5.12% |
| Sep 30, 2023 | 25.31% |
| Jun 30, 2023 | -5.28% |
| Mar 31, 2023 | -8.88% |
| Dec 31, 2022 | 7.78% |
| Sep 30, 2022 | 62.57% |
| Jun 30, 2022 | -29.01% |
| Mar 31, 2022 | -114.47% |
| Dec 31, 2021 | -102.08% |
| Sep 30, 2021 | -236.13% |
| Jun 30, 2021 | -504.18% |